Novavax Inc. (NVAX)

Name: Novavax Inc. (NVAX) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Novavax Inc. (NVAX)

Stock Card

$10.16

$-0.19 (-1.79%)

As on 04-Sep-2026 13:38EDT

Market cap

$1,527 Mln

Revenue (TTM)

$414 Mln

P/E Ratio

P/B Ratio

41.2

Div. Yield

0 %

Novavax (NVAX) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 10.05 High: 10.75

52 Week Range

Low: 6.20 High: 11.97

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-9 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

1.7
Debt to Equity

-1.5
Book Value

$--
EPS

$-1.5
Face value

--
Shares outstanding

164,945,726

10 Years Aggregate

CFO

$-1,761.81 Mln

EBITDA

$-4,055.75 Mln

Net Profit

$-4,392.73 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Novavax (NVAX)	51.1	37.0	-0.4	37.2	7.3	-47.4	-22.8
BSE Sensex	-9.6	-2.7	2.9	-5.0	5.4	5.7	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 04-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021	2020	2019
Novavax (NVAX)	-16.4	66.8	-53.3	-92.8	28.3	2,701.8	-89.2
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	9.1	8.1	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Novavax (NVAX)	10.2	1,527.4	413.8	-247.7	-54.0	--	--	41.2
Arrowhead Pharmaceuticals (ARWR)	84.8	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Ascendis Pharma A/S - ADR	268.4	16,261.1	1,054.4	755.9	5.7	--	19	9.8
Cytokinetics Inc (CYTK)	72.4	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	59.0	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	110.2	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	355.5	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Kymera Therapeutics (KYMR)	118.2	9,718.7	105.0	-299.7	-227.2	-19.4	--	6.6
Madrigal Pharmaceuticals (MDGL)	541.4	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	592.0	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3

Shareholding Pattern

View Details

About Novavax (NVAX)

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a... COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. Read more

President & COO

Mr. John Joseph Trizzino B.S., M.B.A.
President & COO

Mr. John Joseph Trizzino B.S., M.B.A.
Headquarters

Gaithersburg, MD
Website

https://www.novavax.com

FAQs for Novavax (NVAX)

What is the current share price of Novavax Inc (NVAX) Today?

The share price of Novavax Inc (NVAX) is $10.16 (NASDAQ) as of 04-Sep-2026 13:38 EDT. Novavax Inc (NVAX) has given a return of 7.34% in the last 3 years.

What is the current PB & PE ratio of Novavax Inc (NVAX)?

Since, TTM earnings of Novavax Inc (NVAX) is negative, P/E ratio is not available.
The P/B ratio of Novavax Inc (NVAX) is 41.23 times as on 28-Aug-2026, a 696 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.